...
首页> 外文期刊>BMC Cancer >Evaluation of radioactive 125I seed implantation for the treatment of refractory malignant tumours based on a CT-guided 3D template-assisted technique: efficacy and safety
【24h】

Evaluation of radioactive 125I seed implantation for the treatment of refractory malignant tumours based on a CT-guided 3D template-assisted technique: efficacy and safety

机译:基于CT引导3D模板辅助技术的基于CT引导3D模板辅助技术的放射性125I种子植入评价:疗效和安全性

获取原文
           

摘要

BACKGROUND:To observe the medium- and long-term clinical efficacy and safety of radioactive sup125/supI seed implantation for refractory malignant tumours based on CT-guided 3D template-assisted technique.METHODS:Twenty-five patients with refractory malignant tumours who underwent radioactive sup125/supI seed implantation based on CT-guided 3D template-assisted technique were selected. The post-operative adverse reactions were recorded. The number of puncture needles and particles used in the operation, dosimetric parameters, post-operative physical strength scores, and tumour response were statistically analysed. The overall survival time and survival rate were calculated, and the effect and prognosis were assessed.RESULTS:sup125/supI seed implantation was successful in all patients without serious complications. The average number of implanted puncture needles was 17 (19.12?±?13.00), and the median number of particles was 52 (55.12?±?32.97). Dsub90/sub in the post-operative clinical target volume (CTV) (93.24?±?15.70?Gy) was slightly lower than that in the pre-operative CTV (93.92?±?17.60?Gy; P??0.05). The Dsub90/sub in the post-operative planning target volume (PTV) (142.16?±?22.25?Gy) was lower than the pre-operative PTV (145.32?±?23.48?Gy; P??0.05). The tumour responses at 6?months post-operatively: complete remission (CR), 20% (5/25); partial remission (PR), 48% (12/25); stable disease (SD), 24% (6/25); progressive disease (PD), 8% (2/25); CR?+?PR, 68% (17/25); and local control rate, 92% (23/25). The 6-, 12-, and 24-month survival rates were 100, 88, and 52%, respectively. The post-operative physical strength score (Karnofsky performance score, KPS) exhibited a gradual trend towards recovery, which rose to the highest value 12?months after implantation and then decreased slightly, but the average score was still ?90 points. There was one intra-operative pneumothorax, and two patients with superficial malignant tumours developed skin ulcerations. Multivariate analysis of prognosis showed that tumour sites and types were independent risk factors affecting survival. The number of needles and particles and template types were not the factors.CONCLUSIONS:3D template combined with CT-guided radioactive sup125/supI seed implantation can improve the rational distribution of radiation dose in the tumour target area because accurate radioactive sup125/supI particle implantation was achieved. This technique has fewer complications and can further extend the overall survival and improve the quality of life.TRIAL REGISTRATION:Registration number: ChiCTR2000034566 2020/7/10 0:00:00 Retrospectively registered.
机译:背景:基于CT引导3D模板辅助技术,观察放射性 125 I种子植入的中低级临床疗效和安全性的临床疗效和安全性..方法:二十五名患者选择了基于CT引导3D模板辅助技术进行放射性 125 I籽种子植入的难治性恶性肿瘤。记录后术后不良反应。统计分析了操作,剂量测定参数,术后物理强度评分和肿瘤反应中使用的穿刺针和粒子的数量。计算总存活时间和生存率,评估效果和预后。结果: 125 I种子植入在所有患者中都是成功的,没有严重并发症。平均植入的穿刺针数为17(19.12?±13.00),中值数为52(55.12?±32.97)。在术后临床目标体积(CTV)中(93.24?±15.70μl)略低于术前CTV(93.92?±17.60?GY; P ?>?0.05)。在操作后计划目标体积(PTV)中的D 90 (142.16?±22.25?GY)低于术前PTV(145.32?±23.48?GY; P?> ?0.05)。可操作后6月6月的肿瘤反应:完全缓解(CR),20%(5/25);部分缓解(PR),48%(12/25);稳定的疾病(SD),24%(6/25);渐进性疾病(PD),8%(2/25); CR?+?PR,68%(17/25);和局部控制率,92%(23/25)。 6-,12-和24个月的存活率分别为100,88和52%。术后体力评分(Karnofsky性能分数,KPS)展现了渐进的趋势,恢复趋势升至最高值12?植入后数月,然后略微下降,但平均得分仍然存在>?90分。90分。术中有一种术中肺炎,两名患有肤浅的肿瘤患者发育了皮肤溃疡。对预后的多变量分析表明,肿瘤部位和类型是影响存活的独立风险因素。针和粒子和模板类型的数量不是因素。结合:3D模板与CT引导的放射性 125 I籽种植可以提高肿瘤靶区域辐射剂量的合理分布,因为准确达到放射性 125 I颗粒植入。该技术的并发症较少,可以进一步扩展整体生存和提高生活质量.Trial注册:注册号:CHICTR2000034566 2020/7/10 0:00:00回顾性注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号